{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'For patients experiencing a deterioration of asthma during the study, the ICS dose may', 'temporarily be increased up to 4-fold (recorded as LOAC event) for a maximum of 10 days, as', 'indicated and upon recommendation of the physician and/or Investigator. Treatment may then be', 'changed to SCS (severe exacerbation event) or revert back to the original ICS dose depending on', 'the asthma symptoms progression.', 'If a patient experiences 2 or more severe asthma exacerbation events anytime during the study, a', 'permanent change (ie, step up in medium- to high-dose ICS or addition of second controller for', 'patients on high-dose ICS monotherapy; see Appendix A and Appendix B) on their stable-dose', 'background controller medication may occur, as indicated and upon recommendation of the', 'physician and/or Investigator.', 'Screening Period', 'Prior to and during the Screening Period, patients must be on one of the following: stable-dose', 'background therapy of medium-dose ICS with a second controller medication (ie, LABA, LTRA,', 'LAMA, or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller, for', 'at least 3 months, with a stable dose background treatment for >1 month prior to Screening', 'Visit 1.', 'If patients take 2 different ICS, the total daily dose of ICS should be calculated, to evaluate the', 'eligibility criteria on daily dose of ICS, which will be still considered as one controller. Please', 'refer to medium and high-dose of ICS in Appendix A.', 'If the Investigator, based on his/her medical judgment, decides to optimize a patients use of', 'asthma reliever and/or background controller medications prior to the Screening Visit, any', 'changes in ongoing asthma medications must occur more than 1 month in advance of the', 'Screening Visit Day 1, in order to maintain a stable dose for at least 1 month prior to Day 1', '(Section 7.1). The introduction of new controller medications must occur at least 3 months prior', 'to Screening with a stable dose for at least 1 month (Section 7.1).', 'Randomized Treatment Period', 'During this period, patients will continue to take their controller medication(s) used during the', 'Screening Period. The dose of baseline regimen should not be changed, and no adjustments will', 'be made unless the patient experiences 2 or more severe exacerbations events at any time during', 'the study (in which case a step up of controller medication may be allowed). This will be recorded', 'in the eDiary.', 'Patients may be placed on systemic corticosteroids at any time as clinically indicated based on the', 'presence of symptoms consistent with a severe asthma exacerbation event, as per the', \"Investigator's judgment.\", 'Post-treatment Period', 'Upon completing the randomized treatment period, patients not continuing with the long-term,', 'open-label extension study will enter the Post Treatment Period and will proceed to be treated', 'Property of the Sanofi Group - strictly confidential', 'Page 51', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'with the controller medication regimen and dose used during the randomized treatment period,', \"which could be adjusted based on the medical judgment of the Investigator of the patients' asthma\", 'control status.', '8.2.2 Reliever Medication(s)', 'The reliever medication (ie, albuterol/salbutamol or levalbuterol/levosalbutamol) will not be', 'dispensed or supplied by the Sponsor. All other reliever medications other than', 'albuterol/salbutamol or levalbuterol/levosalbutamol should be avoided.', 'Patient(s)/parent(s)/caregiver(s)/legal guardian(s) may administer albuterol/salbutamol or', 'levalbuterol/levosalbutamol reliever medication by MDI as needed during the study. Nebulizer', 'solutions may be used as an alternative delivery method.', 'Criterion for Loss of Asthma Control (LOAC) - Based on Increased Nebulizer Use (in', 'e-CRF):', 'The criterion for LOAC based on a patients increased nebulizer use and the nebulizer-to-puff', 'conversion factor (see tables below), is determined as follows:', 'Study personnel will convert salbutamol/albuterol nebulizer and levosalbutamol/levalbuterol', 'nebulizer use as shown on the following tables:', 'Salbutamol/Albuterol Nebulizer Solution - -Total Daily Dose (mg)', 'Number of Puffs*', '2.5', '4', '5.0', '8', '7.5', '12', '10', '16', '*Conversion factor: salbutamol/albutero? nebulizer solution (2.5 mg) corresponds to 4 puffs', 'Example of salbutamol/albuterol nebulizer-to-puff Conversion: Patient received', '3 salbutamol/albuterol nebulizer treatments (2.5 mg/treatment) between 7 and 11 AM.', 'Total daily = 7.5 mg or 12 puffs', 'Property of the Sanofi Group - strictly confidential', 'Page 52', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}